-
AACR 2015: Report from Day 3
Results of two high-profile clinical trials, among others, are covered on the meeting's third day.
-
AACR 2015: Report from Day 2
Our report on the latest developments in cancer immunotherapy from day 2 at the annual AACR meeting…
-
AACR 2015: Report from Day 1
Presentations from the annual meeting of the American Association for Cancer Research span many cancer immunotherapy topics.
-
Special Issue of Science Devoted to Cancer Immunotherapy
CRI scientists review the state of cancer immunotherapy in the latest issue of Science magazine.
-
What Ever Happened to Coley’s Toxins?
Experts today agree that a 100-year-old therapy cured cancer in some cases. Why did it fall out…
-
Beyond Magic Bullets: Helen Coley Nauts and the Battle for Immunotherapy
How one woman who lacked a college degree took on the cancer establishment and changed the course…
-
Merck’s PD-1 Drug Outperforms Ipilimumab for Treatment of Advanced Melanoma
Data from a phase III trial indicate that Keytruda stands ready to become standard-of-care for advanced melanoma.
-
CRI’s James Allison, Arming the Immune System
The director of CRI's Scientific Advisory Council talks immunotherapy with the New York Times.
-
Big News: FDA Approves Opdivo (Nivolumab) for Lung Cancer
The PD-1 checkpoint inhibitor Opdivo® (nivolumab) is a new treatment option for patients with non-small cell lung…
